{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:31:04Z","timestamp":1790101864062,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00417-020-04710-y","type":"journal-article","created":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T21:02:42Z","timestamp":1588453362000},"page":"1677-1685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term switching between ranibizumab and aflibercept in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy"],"prefix":"10.1007","volume":"258","author":[{"given":"Jae Hui","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,2]]},"reference":[{"key":"4710_CR1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"4710_CR2","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"4710_CR3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","volume":"143","author":"AE Fung","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566\u2013583","journal-title":"Am J Ophthalmol"},{"key":"4710_CR4","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","volume":"117","author":"OP Gupta","year":"2010","unstructured":"Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD (2010) A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 117:2134\u20132140","journal-title":"Ophthalmology"},{"key":"4710_CR5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2009.02.012","volume":"148","author":"M Cho","year":"2009","unstructured":"Cho M, Barbazetto IA, Freund KB (2009) Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 148:70\u201378 e71","journal-title":"Am J Ophthalmol"},{"key":"4710_CR6","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ajo.2010.05.035","volume":"150","author":"AN Stangos","year":"2010","unstructured":"Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP (2010) Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 150:666\u2013673","journal-title":"Am J Ophthalmol"},{"key":"4710_CR7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/bjophthalmol-2013-303444","volume":"98","author":"K Hatz","year":"2014","unstructured":"Hatz K, Prunte C (2014) Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol 98:188\u2013194","journal-title":"Br J Ophthalmol"},{"key":"4710_CR8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bjo.2011.203893","volume":"96","author":"MS Eghoj","year":"2012","unstructured":"Eghoj MS, Sorensen TL (2012) Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 96:21\u201323","journal-title":"Br J Ophthalmol"},{"key":"4710_CR9","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"4710_CR10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ajo.2012.04.020","volume":"154","author":"DJ Browning","year":"2012","unstructured":"Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW (2012) Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 154:222\u2013226","journal-title":"Am J Ophthalmol"},{"key":"4710_CR11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2013.02.017","volume":"156","author":"B Bakall","year":"2013","unstructured":"Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB (2013) Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 156:15\u201322 e11","journal-title":"Am J Ophthalmol"},{"key":"4710_CR12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ajo.2013.03.030","volume":"156","author":"Y Yonekawa","year":"2013","unstructured":"Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, Vavvas DG, Miller JW, Kim IK (2013) Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 156:29\u201335 e22","journal-title":"Am J Ophthalmol"},{"key":"4710_CR13","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/IAE.0b013e31828e8551","volume":"33","author":"N Kumar","year":"2013","unstructured":"Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB (2013) Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33:1605\u20131612","journal-title":"Retina"},{"key":"4710_CR14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00417-013-2553-7","volume":"252","author":"FM Heussen","year":"2014","unstructured":"Heussen FM, Shao Q, Ouyang Y, Joussen AM, Muller B (2014) Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 252:909\u2013915","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4710_CR15","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s12325-019-00971-0","volume":"36","author":"T Empeslidis","year":"2019","unstructured":"Empeslidis T, Storey M, Giannopoulos T, Konidaris V, Tranos PG, Panagiotou ES, Voudouragkaki IC, Konstas AG (2019) How successful is switching from bevacizumab or ranibizumab to aflibercept in age-related macular degeneration? A systematic overview. Adv Ther 36:1532\u20131548","journal-title":"Adv Ther"},{"key":"4710_CR16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.survophthal.2018.02.004","volume":"63","author":"I Mantel","year":"2018","unstructured":"Mantel I, Gillies MC, Souied EH (2018) Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. Surv Ophthalmol 63:638\u2013645","journal-title":"Surv Ophthalmol"},{"key":"4710_CR17","doi-asserted-by":"publisher","unstructured":"Gale RP, Pearce I, Eter N, Ghanchi F, Holz FG, Schmitz-Valckenberg S, Balaskas K, Burton BJL, Downes SM, Eleftheriadis H, George S, Gilmour D, Hamilton R, Lotery AJ, Patel N, Prakash P, Santiago C, Thomas S, Varma D, Walters G, Williams M, Wolf A, Zakri RH, Igwe F, Ayan F (2019) Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314251","DOI":"10.1136\/bjophthalmol-2019-314251"},{"key":"4710_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","volume":"29","author":"A Laude","year":"2010","unstructured":"Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Koh AH, Wong TY, Aung T (2010) Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 29:19\u201329","journal-title":"Prog Retin Eye Res"},{"key":"4710_CR19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/IAE.0000000000002412","volume":"39","author":"RF Spaide","year":"2019","unstructured":"Spaide RF (2019) New proposal for the pathophysiology of type 3 neovascularization as based on multimodal imaging findings. Retina 39:1451\u20131464","journal-title":"Retina"},{"key":"4710_CR20","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.survophthal.2017.01.008","volume":"62","author":"ASH Tsai","year":"2017","unstructured":"Tsai ASH, Cheung N, Gan ATL, Jaffe GJ, Sivaprasad S, Wong TY, Cheung CMG (2017) Retinal angiomatous proliferation. Surv Ophthalmol 62:462\u2013492","journal-title":"Surv Ophthalmol"},{"key":"4710_CR21","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/IAE.0000000000000488","volume":"35","author":"A Nagiel","year":"2015","unstructured":"Nagiel A, Sarraf D, Sadda SR, Spaide RF, Jung JJ, Bhavsar KV, Ameri H, Querques G, Freund KB (2015) Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography. Retina 35:638\u2013647","journal-title":"Retina"},{"key":"4710_CR22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.oret.2018.09.001","volume":"3","author":"U Chakravarthy","year":"2019","unstructured":"Chakravarthy U, Bezlyak V, Sagkriotis A, Griner R, Skelly A, Boyer DS, Milnes F (2019) Effectiveness of continued ranibizumab therapy in neovascular age-related macular degeneration versus switch to aflibercept: real world evidence. Ophthalmol Retina 3:8\u201315 e11","journal-title":"Ophthalmol Retina"},{"key":"4710_CR23","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00417-018-4061-2","volume":"256","author":"D Barthelmes","year":"2018","unstructured":"Barthelmes D, Nguyen V, Walton R, Gillies MC, Daien V (2018) A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013-2016. The fight retinal blindness! Project. Graefes Arch Clin Exp Ophthalmol 256:1839\u20131846","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4710_CR24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ceo.13114","volume":"46","author":"KK Dansingani","year":"2018","unstructured":"Dansingani KK, Gal-Or O, Sadda SR, Yannuzzi LA, Freund KB (2018) Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of 'expanded spectra' - a review. Clin Exp Ophthalmol 46:189\u2013200","journal-title":"Clin Exp Ophthalmol"},{"key":"4710_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1\u20138","journal-title":"Retina"},{"key":"4710_CR26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00006982-199515020-00003","volume":"15","author":"RF Spaide","year":"1995","unstructured":"Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA (1995) Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 15:100\u2013110","journal-title":"Retina"},{"key":"4710_CR27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","volume":"53","author":"CW Wong","year":"2016","unstructured":"Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, Cheung CMG (2016) Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53:107\u2013139","journal-title":"Prog Retin Eye Res"},{"key":"4710_CR28","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1136\/bjophthalmol-2016-310074","volume":"101","author":"S Yadav","year":"2017","unstructured":"Yadav S, Parry DG, Beare NAV, Pearce IA (2017) Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians. Br J Ophthalmol 101:1377\u20131380","journal-title":"Br J Ophthalmol"},{"key":"4710_CR29","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","volume":"156","author":"A Oishi","year":"2013","unstructured":"Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, Kita M, Nagai T, Fujihara M, Bessho N, Uenishi M, Kurimoto Y, Negi A (2013) Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol 156:644\u2013651","journal-title":"Am J Ophthalmol"},{"key":"4710_CR30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/eye.2013.179","volume":"27","author":"M Inoue","year":"2013","unstructured":"Inoue M, Arakawa A, Yamane S, Kadonosono K (2013) Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy. Eye (Lond) 27:1013\u20131020 quiz 1021","journal-title":"Eye (Lond)"},{"key":"4710_CR31","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.oret.2019.04.018","volume":"3","author":"GT Kokame","year":"2019","unstructured":"Kokame GT, deCarlo TE, Kaneko KN, Omizo JN, Lian R (2019) Anti-vascular endothelial growth factor resistance in exudative macular degeneration and polypoidal choroidal vasculopathy. Ophthalmol Retina 3:744\u2013752","journal-title":"Ophthalmol Retina"},{"key":"4710_CR32","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2147\/OPTH.S50634","volume":"7","author":"M Miura","year":"2013","unstructured":"Miura M, Iwasaki T, Goto H (2013) Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis. Clin Ophthalmol 7:1591\u20131595","journal-title":"Clin Ophthalmol"},{"key":"4710_CR33","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1097\/IAE.0000000000000236","volume":"34","author":"M Saito","year":"2014","unstructured":"Saito M, Kano M, Itagaki K, Oguchi Y, Sekiryu T (2014) Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab. Retina 34:2192\u20132201","journal-title":"Retina"},{"key":"4710_CR34","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00417-014-2838-5","volume":"253","author":"Y Kawashima","year":"2015","unstructured":"Kawashima Y, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ueda-Arakawa N, Yoshikawa M, Takahashi A, Yoshimura N (2015) Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 253:1471\u20131477","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4710_CR35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10384-015-0411-3","volume":"60","author":"M Saito","year":"2016","unstructured":"Saito M, Kano M, Itagaki K, Ise S, Imaizumi K, Sekiryu T (2016) Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection. Jpn J Ophthalmol 60:35\u201341","journal-title":"Jpn J Ophthalmol"},{"key":"4710_CR36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","volume":"137","author":"MC Gillies","year":"2019","unstructured":"Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL (2019) Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol 137:372\u2013379","journal-title":"JAMA Ophthalmol"},{"key":"4710_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.02.019","volume":"165","author":"HJ Cho","year":"2016","unstructured":"Cho HJ, Kim KM, Kim HS, Han JI, Kim CG, Lee TG, Kim JW (2016) Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol 165:1\u20136","journal-title":"Am J Ophthalmol"},{"key":"4710_CR38","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1136\/bjophthalmol-2015-308090","volume":"100","author":"D Barthelmes","year":"2016","unstructured":"Barthelmes D, Campain A, Nguyen P, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, Guymer R, Essex RW, Morlet N, Gillies MC (2016) Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Br J Ophthalmol 100:1640\u20131645","journal-title":"Br J Ophthalmol"},{"key":"4710_CR39","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R (2015) Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol 160:725\u2013731 e721","journal-title":"Am J Ophthalmol"},{"key":"4710_CR40","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ophtha.2015.12.001","volume":"123","author":"S Mueller","year":"2016","unstructured":"Mueller S, Agostini H, Ehlken C, Bauer-Steinhusen U, Hasanbasic Z, Wilke T (2016) Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment. Ophthalmology 123:876\u2013883","journal-title":"Ophthalmology"},{"key":"4710_CR41","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A (2019) Brolucizumab: first approval. Drugs 79:1997\u20132000","journal-title":"Drugs"},{"key":"4710_CR42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72\u201384","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04710-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-020-04710-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04710-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T16:43:23Z","timestamp":1620060203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-020-04710-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,2]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4710"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-04710-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,2]]},"assertion":[{"value":"25 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board of Kim\u2019s Eye Hospital (Seoul, South Korea). This study was conducted in accordance with the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not obtained in this study. Identifying information about participants was not presented in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}